---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000047"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T04:01:06.880064+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ligand reports Merck vaccine FDA approval milestone and Takeda soticlestat Phase 3 miss

## Summary
- FDA approved Merck's CAPVAXIVE; Ligand earns $2M milestone + royalties on net sales.
- Takeda's soticlestat missed primary endpoints in Dravet (SKYLINE) and Lennox-Gastaut (SKYWAY) Phase 3 trials.
- Ligand owns 13% royalty on soticlestat from $30M Ovid deal; clinical miss reduces royalty value.
- SKYLINE narrowly missed seizure reduction primary; showed significant secondary endpoint effects.
- SKYWAY missed primary endpoint of reduction in major motor drop seizures.

## SEC filing metadata
- accession: 0000886163-24-000047
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000047/0000886163-24-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000047/lgnd-20240618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000047
- JSON: https://secwatch.observer/filing/0000886163-24-000047.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.